BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology

First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs on track for IND-enabling activities in 2022 Multi kinase inhibitor, BTX-A51, to continue in Phase 1 with expansion into s... Biopharmaceuticals, Oncology, Venture Capital BioTheryX, protein homeostasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news